City
Epaper

Pfizer to send 50 million COVID-19 vaccines to India with conditions

By ANI | Updated: May 26, 2021 20:55 IST

US pharmaceutical giant Pfizer is likely to supply 50 million COVID-19 vaccines to India in 2021, albeit with a few conditions, sources told ANI on Wednesday.

Open in App

US pharmaceutical giant Pfizer is likely to supply 50 million COVID-19 vaccines to India in 2021, albeit with a few conditions, sources toldon Wednesday.

However, the drugmaker has asked for relaxations in some clauses, including indemnification for its shots, sources informed.

Meanwhile, Moderna, another pharmaceutical giant in the US, sources said is expecting to start manufacturing its COVID-19 vaccines in India following an analysis with Cipla, a pharmaceutical company based in Mumbai, among other Indian firms.

Earlier, both drugmakers had allegedly refused to send vaccines directly to the state governments of Delhi and Punjab, claiming that they will only deal with the Central government.

"We have spoken to Pfizer and Moderna for vaccines, and both the companies have refused to sell vaccines directly to us. They have said that they will deal with the Government of India alone," Delhi Chief Minister Arvind Kejriwal had said on Monday.

India is moving towards vaccine sufficiency as inoculations with the Russian vaccine Sputnik V began in the country earlier this month.

Sources toldthat India and Russia are planning to manufacture around 35-40 million doses every month that will start from August or September.

Before the transfer of technology in August for local production, Russia will send close to 18 million Sputnik V doses to India - 3 million in May, 5 million in June and 10 million in July, said sources.

On May 24, the Russian Direct Investment Fund (RDIF) and Panacea Biotec, one of the leading pharmaceutical producers in India, had launched the production of the Sputnik V COVID-19 vaccine.

Other sites of production of the Sputnik V vaccines are - Hetero Biologics, Virchow Biotech, Gland Pharma, Stelis Biopharma and Shilpa Medicare.

India has also been using two vaccines - Covishield by the Serum Institute of India (SII) and Covaxin by the Hyderabad-based Bharat Biotech. According to the sources, India is expected to produce approximately 20-25 crore vaccines per month.

Sources informed that two next-generation vaccines will also be made in India. One is the DNA vaccine by Cadila Zydus and the other is an mRNA vaccine by Gennova Biopharmaceuticals Ltd. Both vaccines have shown promise and are expected to reduce international dependence for the supply of doses.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Stelis Biopharma Private LimiteddelhimumbaiArvind KejriwalCipla limitedPfizer`delhiCiplaDelhi capitalSouth delhi district administration
Open in App

Related Stories

NationalDelhi Bandh: Chandani Chowk Markets Closed in Respect for Pahalgam Terror Attack (Watch Video)

ThaneThane: Fire Breaks Out in Scrap Warehouse in Bhiwandi, Damage Estimated in Millions (Watch Video)

MumbaiMumbai on High Alert, Security Tightened at Public Places After Pahalgam Terror Attack

MumbaiMumbai Shocker: 8-Year-Old Dies After Falling into Water-Filled Pit Dug by MMRDA for Metro Work

MaharashtraPahalgam Terror Attack: Flight Carrying First Batch of 65 Stranded Maharashtra Tourists Lands in Mumbai

International Realted Stories

International'This was a terror attack, plain and simple', US House Committee slams NYT's Pahalgam report

International"Pakistan's backing of terrorism corroded spirit of goodwill": Indian Embassy in US on suspension of Indus Water Treaty

InternationalPahalgam attack: Indian High Commission in London holds prayer meet, pays solemn tribute

InternationalIncreases in vaccine-preventable disease outbreaks threaten years of progress, warn WHO, UNICEF, Gavi

International"Shock for the world": Russian MLA Abhay Kumar Singh on Pahalgam terror attack